Diabetic Under 70 (Diabetics Below 70)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00516204
Recruitment Status : Completed
First Posted : August 15, 2007
Last Update Posted : October 30, 2014
Information provided by (Responsible Party):

Brief Summary:
A screening project of diabetics with a very high cardiovascular risk (e.g. diabetes plus coronary heart disease) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <70mg/dl for such patients with very high risk) are screened. The doctors therapy decisions after the screening will be documented and 8-10 weeks later the lipid profile of each patient will be evaluated again. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Condition or disease
Diabetes Hyperlipidemia Atherosclerosis

Study Type : Observational
Actual Enrollment : 685 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diabetic Under 70 (Diabetics Below 70)
Study Start Date : July 2007
Actual Primary Completion Date : December 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

Patients at very high risk
Patients at high risk
Patients at medium risk
Patients at low risk

Primary Outcome Measures :
  1. Cholesterol levels [ Time Frame: After 4 weeks ]
    Cholesterol levels from high risk patients after 4 weeks of cholesterol-lowering drug therapy under target values

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Male and female secondary prevention patients with: coronary disease with event: acute coronary syndrome, status post MI, PTCA, CABG, angiographically verified), PAVK (min. IIb or S.p. revascularization), stroke/TIA, carotis-plaque (asymptomatic min. 70% or S.p. revascularization), Diabetes Mellitus (type I, II)

Inclusion Criteria:

  • Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.) who already receive cholesterol-lowering therapy

Exclusion Criteria:

  • Diabetics w/o CVD; diabetics who do not receive cholesterol-lowering therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00516204

Research Site
Vienna, Austria
Sponsors and Collaborators
Study Chair: Michael Roden, MD Chairs of the Austrian Diabetes Society

Responsible Party: AstraZeneca Identifier: NCT00516204     History of Changes
Other Study ID Numbers: NIS-CAT-CRE-2007/3
First Posted: August 15, 2007    Key Record Dates
Last Update Posted: October 30, 2014
Last Verified: October 2014

Keywords provided by AstraZeneca:
Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.)

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases